07-2019-InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
(WorldNews Netherlands)

InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa IFX-1treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HS IFX-1suppressed C5a levels dose dependently and exhibited a favorable safety profile with low anti-drug antibody rates Open-labelextension study is ongoing, InflaRx plans end of Phase II regulatory discussions after completion of SHINE trial Conference call on July 19, 2019 at 8 am EDT, 2 pm CEST Jena, Germany, July 18, 2019- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...